Exact Sciences Prices Public Offering of 7M Shares | GenomeWeb

NEW YORK(GenomeWeb) – Exact Sciences today priced the public offering of 7 million shares of its common stock at $25.50 per share.

Net proceeds will be used to expand the commercialization of the Cologuard colorectal cancer screening test, which was approved by the US Food and Drug Administration last August. Proceeds will also be used to fund product development and for general corporate and working capital purposes. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.